Biogen (BIIB) Cash from Investing Activities (2009 - 2026)

Biogen (BIIB) has reported Cash from Investing Activities for 18 consecutive years, with -$209.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 342.92% year-over-year to -$209.5 million; the TTM figure through Mar 2026 stood at -$1.5 billion (down 96.45% YoY), while the FY2025 annual figure was -$1.4 billion, down 71.56% from the prior year.
• Cash from Investing Activities came in at -$209.5 million for Q1 2026 at Biogen, up from -$1.2 billion in the prior quarter.
• The five-year high for Cash from Investing Activities was $1.7 billion in Q3 2022, with the low at -$1.7 billion in Q3 2023.
• Average Cash from Investing Activities over 5 years is -$288.5 million, with a median of -$141.1 million recorded in 2022.
• Across the five-year window, Cash from Investing Activities jumped 815.84% in 2022 and plunged 6522.04% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$141.1 million in 2022, then tumbled by 362.3% to -$652.3 million in 2023, then jumped by 97.15% to -$18.6 million in 2024, then slumped by 6522.04% to -$1.2 billion in 2025, then jumped by 82.99% to -$209.5 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$209.5 million, -$1.2 billion, and -$35.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.